The company's commitment to advancing human potential through science is evident in its transformative approach and a diverse portfolio of specialize...
The ODD granted to RZ-001 in HCC may allow it to receive 7 years of marketing exclusivity upon product approval, exemption from user fee and tax credits. T...
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...
Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in In...
Carcinotech has raised $5.3 million of funding as the company looks to build on its traction in the UK and Europe, with US expansion planned later this yea...
Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong&...
The three partners are joining forces to develop drug candidates that modulate the immune response of cancer patients and block the development of metast...
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East...
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo&nbs...
Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant ...
First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free surv...
Thermo Fisher Scientific, the world leader in the service of science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Ag...
AbZelect™ and AbZelectPRO™ platforms enable the rapid generation and selection of high-yielding mammalian CHO cell lines for therapeutic protei...
© 2024 Biopharma Boardroom. All Rights Reserved.
